SOR-C13 possibly disrupts how TRPV6 functions

SOR-C13 possibly disrupts how TRPV6 functions

User Photo
Cancer-News

1 year
197 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jack Stewart, CSO of Soricimed Biopharma discusses SOR-C13, a selective inhibitor of TRPV6, binds with affinity and disrupts how TRPV6 functions.
Up Next Autoplay